Oxford Nanopore Technologies /£ONT

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc, trading under the ticker ONT, operates in the biotechnology sector, focusing on the development of nanopore technology for DNA and RNA sequencing. Founded in 2005 and publicly listed, the company's innovative technology facilitates real-time, scalable, and accessible biological research, with applications ranging from healthcare to environmental science. Based in the UK, Oxford Nanopore has revolutionized the approach to molecular analysis by providing a direct and electric characterization of single molecules.

Ticker

£ONT
Sector

Primary listing

LSE

Employees

1,325

ONT Metrics

BasicAdvanced
£1.4B
-
-£0.15
0.83
-

What the Analysts think about ONT

Analyst ratings (Buy, Hold, Sell) for Oxford Nanopore Technologies stock.

Bulls say / Bears say

Oxford Nanopore reported H1 2025 revenue of approximately £105 million, a 28 percent constant-currency increase driven by 59 percent growth in the PromethION product range, surpassing expectations and underscoring robust market demand. (Reuters)
Underlying revenue growth in the second half of 2024 accelerated to approximately 34 percent on a constant-currency basis, demonstrating strong operational momentum entering 2025. (LSE)
The stock rebounded 75 percent over the past year, supported by increased stakes from major investors such as Larry Ellison’s EIT Oxford Holdings and Novo Holdings, reflecting confidence in the company’s strategic trajectory. (Financial Times)
Co-founder and CEO Gordon Sanghera plans to step down by the end of 2026, introducing leadership transition risk during a critical growth phase. (Financial Times)
FY 2025 guidance remains conservative, with projected revenue growth of 20–23 percent on a constant-currency basis and adjusted operating expense growth of 3–4 percent, indicating potential deceleration relative to medium-term targets. (LSE)
The company’s vulnerability as a takeover target is rising following the expiration of CEO veto rights, with high-profile suitors such as Thermo Fisher and Danaher reportedly showing interest, potentially distracting management and impacting valuation. (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

ONT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ONT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £ONT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs